VivoSeq
Other

SGLT2 Inhibitors

0

Pipeline Programs↗

7

Active Trials↗

2

Companies Involved↗

SGLT2 Inhibitors is an early-stage landscape with 0 programs across 2 companies. The most active players are Mario Negri Institute for Pharmacological Research, Novo Nordisk.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

0 programs

PreclinicalNovo Nordisk logo

Novo Nordisk

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Completed4 · 27%
Recruiting3 · 20%
Active, not recruiting2 · 13%
Unknown status2 · 13%
Not yet recruiting1 · 7%
Withdrawn1 · 7%
Other2 · 13%

Clinical Trials

Trial Activity

15 trials

SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning
Recruiting·NNational Taiwan University Hospital·Phase 3·NCT06142474·450 enrolled
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT05057806·30 enrolled
Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)
Recruiting·UUniversity of Virginia·Phase 1·NCT06600178·150 enrolled
SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers
Active, not recruiting·UUniversity of Patras·N/A·NCT05408936·80 enrolled
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Active, not recruiting·OOhio State University·N/A·NCT07188545·23,280,000 enrolled
Effect of SGLT2 Inhibitors on Anemic CKD Patients
Not yet recruiting·SSohag University·N/A·NCT07334145·60 enrolled
SGLT2 Inhibitors in Treating Patients With PCOS
Enrolling by invitation·SShanghai 10th People's Hospital·N/A·NCT05966792·80 enrolled
Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT03560323·41 enrolled
SGLT2 Inhibitors in Patients With PCOS
Completed·SShanghai 10th People's Hospital·Phase 4·NCT04700839·68 enrolled
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
Completed·Novo Nordisk logoNovo Nordisk·Phase 3·NCT02964247·303 enrolled
Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors
Completed·—·Phase 4·NCT06825156·60 enrolled
Pharmacogenetics of SGLT2 Inhibitors
Terminated·UUniversity of Maryland, Baltimore·Phase 4·NCT02462421·30 enrolled
SGLT2 Inhibitors in Glomerular Hyperfiltration
Withdrawn·Mario Negri Institute for Pharmacological Research logoMario Negri Institute for Pharmacological Research·Phase 2·NCT04143581
Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors
Unknown status·UUniversity of Turin, Italy·N/A·NCT03917758·30 enrolled
Using of SGLt2 Inhibitors in Patients With Type 2 DM
Unknown status·—·N/A·NCT06268977·400 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)